|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||30.560 - 30.830|
|52 Week Range||25.250 - 36.820|
|PE Ratio (TTM)||21.80|
|Forward Dividend & Yield||1.03 (3.53%)|
|1y Target Est||N/A|
In September 2017, the FDA approved Merck’s (MRK) Keytruda for the treatment of individuals with relapsing or recurrent metastatic GEJ (gastroesophageal junction) adenocarcinoma with PDL11-expressing tumors, ...
Roche is now a real competitor with a potential first treatment in advanced lung cancer, an analyst said Monday.
Today, Shire (SHPG) appointed a new chief financial officer. The shares are sliding lower today after its rival Roche (RHHBY) unveiled study results that showed its Hemlibra hemophilia drug trial reduced treated bleeds in hemophilia A patients without indicators. The news is an added blow for Shire.
It isn’t every day that a major drug maker unveils a big clinical trial win. Roche Holding (RHHBY) shares were on the rise Monday after the company released data from two separate studies for its new cancer and hemophilia drugs. The immuno-cancer drug Tecentriq advanced as a treatment for advanced lung cancer when mixed with Roche’s other cancer drug Avastin and chemotherapy.
Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.
Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.
Roche announced two trial wins for its cancer and haemophilia drugs on Monday, boosting its shares and weighing on the stocks of its main rivals. The Basel-based health group said its immunotherapy Tecentriq had made advances against lung cancer when mixed with other treatments, and its haemophilia agent Hemlibra had reduced bleeds in a new group of patients. Roche's shares rose as much as 5.6 percent, adding roughly $11 billion to its market capitalisation and making it the best performer on the Swiss Market Index.
Roche Holding AG shares surged after two experimental medicines for cancer and hemophilia succeeded in much-anticipated patient trials, boding well for the Swiss drugmaker’s ability to grow as its biggest ...
This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The U.S. Food and Drug Administration on Thursday approved Roche's Hemlibra, a new medicine for haemophilia A that the Swiss drugmaker is counting on to help to offset eroding sales of older medicines going off patent. The U.S. regulator approved Roche's drug, previously known as ACE910, or emicizumab, as a once-weekly injection for adults and paediatric patients with haemophilia A who have developed inhibitors, or resistance, to other treatments.
The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio ...
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Swiss drugmaker Roche on Friday won a key European panel's recommendation for its multiple sclerosis drug Ocrevus, which is on track for nearly $1 billion in sales in 2017 after winning U.S. regulators' go-ahead earlier this year. Ocrevus got a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS). Final approval falls to the European Commission, but it generally follows the CHMP recommendation.
Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.
In 3Q17, Roche’s (RHHBY) Gazyva generated revenues of 69 million Swiss francs, which reflected ~34% growth on a year-over-year (or YoY) basis.